News | July 01, 2022
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
Both manufacturing facilities are based out of Benguluru, India
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Subscribe To Our Newsletter & Stay Updated
